Martin Körbling

Medicine · Health Sciences

43h-index9.7kcitations160works0.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Hematopoietic Stem Cell Transplantation(74), Lymphoma Diagnosis and Treatment(51), Chronic Lymphocytic Leukemia Research(41), Mesenchymal stem cell research(20), Chronic Myeloid Leukemia Treatments(18)

Publications160 total

Table A1 from Updated Results of Rituximab Pre- and Post-BEAM with or without <sup>90</sup>Yttrium Ibritumomab Tiuxetan during Autologous Transplant for Diffuse Large B-cell Lymphoma
2023Open Access
Figure A1 from Updated Results of Rituximab Pre- and Post-BEAM with or without <sup>90</sup>Yttrium Ibritumomab Tiuxetan during Autologous Transplant for Diffuse Large B-cell Lymphoma
2023Open Access
Data from Updated Results of Rituximab Pre- and Post-BEAM with or without <sup>90</sup>Yttrium Ibritumomab Tiuxetan during Autologous Transplant for Diffuse Large B-cell Lymphoma
2023Open Access
Table A1 from Updated Results of Rituximab Pre- and Post-BEAM with or without <sup>90</sup>Yttrium Ibritumomab Tiuxetan during Autologous Transplant for Diffuse Large B-cell Lymphoma
2023Open Access
Figure A1 from Updated Results of Rituximab Pre- and Post-BEAM with or without <sup>90</sup>Yttrium Ibritumomab Tiuxetan during Autologous Transplant for Diffuse Large B-cell Lymphoma
2023Open Access
Data from Updated Results of Rituximab Pre- and Post-BEAM with or without <sup>90</sup>Yttrium Ibritumomab Tiuxetan during Autologous Transplant for Diffuse Large B-cell Lymphoma
2023Open Access
Updated Results of Rituximab Pre- and Post-BEAM with or without 90Yttrium Ibritumomab Tiuxetan during Autologous Transplant for Diffuse Large B-cell Lymphoma
Clinical Cancer Research·2018· 13 cited
Effect of nonpermissive HLA-DPB1 mismatches after unrelated allogeneic transplantation with in vivo T-cell depletion
Blood·2018· 29 citedOpen Access
Bfr (bendamustine, fludarabine, rituximab) Nonmyeloablative Allogeneic Conditioning for Lymphoid Malignancies: 8-Year Results
Blood·2017· 1 cited
Safety of Addition of Inotuzumab Ozogamicin (CMC 544) to Bendamustine, Fludarabine, and Rituximab (BFR) Allogeneic Conditioning for Lymphoid Malignancies
Blood·2017· 1 cited
Ofatumumab, Very Late Antigen 4 (VLA4), and Dendritic Cells in Patients Undergoing Autologous Peripheral Blood Stem Cell (PBSC) Mobilization and Transplantation (ASCT) for Relapsed b-Cell Non-Hodgkin's Lymphomas (NHL)
Blood·2017
Feasibility of Lenalidomide Therapy for Persistent Chronic Lymphocytic Leukemia after Allogeneic Transplantation
Biology of Blood and Marrow Transplantation·2017· 7 citedOpen Access
Ofatumumab Plus Ifosfamide/Etoposide (OIE) Followed By Autologous Stem Cell Transplantation (ASCT) in Patients with b-Cell Non-Hodgkin's Lymphomas (NHL)
Blood·2016
Outcome of Patients with Multiple Myeloma and CKS1B Gene Amplification after Autologous Hematopoietic Stem Cell Transplantation
Biology of Blood and Marrow Transplantation·2016· 31 citedOpen Access
Results of a 2‐arm, phase 2 clinical trial using post‐transplantation cyclophosphamide for the prevention of graft‐versus‐host disease in haploidentical donor and mismatched unrelated donor hematopoietic stem cell transplantation
Cancer·2016· 85 citedOpen Access
Long-term outcomes of non-myeloablative allogeneic stem cell transplantation (alloSCT) in patients with relapsed mantle cell lymphoma (MCL).
Journal of Clinical Oncology·2016· 2 cited
Results of a Two-Arm Phase II Clinical Trial Using Post-Transplantation Cyclophosphamide for Prevention of Graft-Versus-Host Disease in Haploidentical and Mismatched Unrelated Donors Hematopoietic Stem-Cell Transplantation
Blood·2015· 2 cited
In-Vivo Purging with Rituximab (R) Followed By Z/BEAM Vs BEAM/R Autologous Stem Cell Conditioning for Relapsed Diffuse Large B-Cell Lymphoma (DLBCL) Patients (pts): Mature Results from a Combined Analysis of 3 Trials
Blood·2015· 3 cited
Comparison of Survival in Patients with T Cell Lymphoma after Autologous and Allogeneic Stem Cell Transplantation as a Frontline Strategy or in Relapsed Disease
Biology of Blood and Marrow Transplantation·2015· 49 citedOpen Access
Clinical Characteristics and Outcomes in Patients with Multiple Myeloma and CKS1B Gene Gain/Amplification after Autologous Stem Cell Transplantation
Blood·2014· 1 cited
page 1 of 8Next →

Frequent Co-authors

Richard E. Champlin(30), Paolo Anderlini(24), Sergio Giralt(19), Issa F. Khouri(19), Chitra Hosing(13), Marcos de Lima(12), Rima M. Saliba(12), Uday Popat(12), Elizabeth J. Shpall(11), Gabriela Rondón(10), Börje S. Andersson(10), Donna Przepiorka(9), Amin M. Alousi(7), Partow Kebriaei(7), Muzaffar H. Qazilbash(7), Stefan O. Ciurea(7), Michèle L. Donato(7), Koen van Besien(6), Rakesh Mehra(6), John D. McMannis(6)